The user experienced improved hair density and thickness after using finasteride and dermarolling for 2.5 years but noticed hair loss when doing anaerobic exercise. They increased their finasteride dose and continued dermarolling but are considering not starting minoxidil due to its perceived hassle and uncertain long-term benefits.
Dutasteride promotes more hair regrowth than Minoxidil. Users discuss combining treatments for better results and share personal experiences with side effects.
The conversation discusses whether creatine causes hair loss for those using finasteride or dutasteride, with some suggesting creatine might increase DHT or upregulate androgen receptors, potentially leading to hair loss. Others argue the evidence is not conclusive, citing limited studies and personal anecdotes, with some avoiding creatine as a precaution.
The conversation discusses the effectiveness of hair loss treatments, specifically finasteride and dutasteride. The conclusion is that dutasteride significantly reduces DHT levels and may be more effective than finasteride for long-term hair retention, with some users reporting personal experiences and side effects.
The conversation is about a person's hair loss treatment regimen, which includes Minoxidil, low-dose Finasteride, Pyrilutamide, weekly use of a derma roller, and hair loss shampoo. They chose these treatments to minimize systemic effects and plan to share their results for others' benefit.
A potential new treatment for hair loss, Pyrilutamide, and the discussion of whether or not people should still be taking traditional treatments like Minoxidil and Finasteride with it.
Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.
A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.
A user's progress using minoxidil and dutasteride mesotherapy to treat hair loss, with advice from other users on whether or not to continue the treatment. Suggestions included trying oral treatments such as finasteride and RU58841, and considering a hair transplant for more significant results.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
The progress of PhaseI of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Kintor Pharma finished enrolling and dosing participants in a PhaseI trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone PhaseI trials in women, with potential commercialization by 2027.
HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phaseI trial.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in PhaseI trial, users seek group buy for research chemical.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
Hope Medicine's announcement of the HMI-115 PhaseII clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
The conversation discusses the completion of a PhaseII trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user is using a combination of hair loss treatments including finasteride, stemoxydine, oral minoxidil, RU58841, dermastamping, ketoconazole shampoo, collagen, Viviscal, and biotin, and has improved their diet. Despite these efforts, they are still experiencing hair shedding and scalp itchiness, and are considering increasing their minoxidil dosage or starting dutasteride.
A 22-year-old man shared his experience with hair loss, which began at age 20, and his treatment with finasteride and oral minoxidil, planning to add microneedling. Since experiencing hair loss, he has changed his perspective and now notices other men's hair loss more, viewing them positively, and others in the conversation relate to this shift in perception.
Hair loss discussion mentions HMI-115 efficacy in 3 months after PhaseII study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phaseII clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
The conversation discusses GT20029, a drug in PhaseII trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.